Related Experiment Videos
A robust homogeneous binding assay for alpha4beta2 nicotinic acetylcholine receptor
1The National Center for Drug Screening, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Graduate School of Chinese Academy of Sciences, Shanghai 201203, China.
Acta Pharmacologica Sinica
|September 22, 2005
Summary
A novel scintillation proximity assay (SPA) was developed for high-throughput screening (HTS) of alpha4beta2 nicotinic acetylcholine receptor (nAChR) modulators. This robust assay identified 17 novel compounds with high binding affinity for potential therapeutic applications.
Area of Science:
- Pharmacology
- Neuroscience
- Assay Development
Background:
- The alpha4beta2 nicotinic acetylcholine receptor (nAChR) is a key target for neurological disorders.
- Identifying novel modulators requires efficient screening methods.
Purpose of the Study:
- To develop a homogeneous high-throughput screening (HTS) assay using scintillation proximity assay (SPA) technology.
- To identify novel modulators of the alpha4beta2 nAChR.
Main Methods:
- Development of an SPA-based HTS assay using HEK293 cells expressing alpha4beta2 nAChR and [(3)H]cytisine.
- Validation against filter binding and application to screen a library of 32,000 compounds.
- Secondary screening using intracellular calcium measurements to confirm bioactivity.
Main Results:
- The SPA assay demonstrated comparable results to filter binding for reference compounds.
- An initial HTS campaign identified 54 compounds with significant competitive inhibition.
- Secondary screening confirmed 17 novel compounds with high binding affinity (K(i)<2 µmol/L) and identified 8 antagonists.
Conclusions:
- The developed homogeneous SPA assay is efficient, automatable, and robust for HTS of alpha4beta2 nAChR modulators.
- This assay platform has potential applications for other membrane receptors and ion channels.